Prostate cancer: the new evidence base for diagnosis and treatment

References

• Kramer B. S., Gohagan J. K., Prorok P. C. Cancer Screening: Screening and Practice. Marcel Dekker Inc, New York 1999
   Google Scholar
• US Preventative Services Task Force. Guide to Clinical Preventative Services. Alexandria, Va, International Medical Publishing
   Google Scholar
• Smith D. P., Supramaniam R., Coates M. S., Armstrong B. K. Prostate Cancer in New South Wales in 1972 to 1994. NSW Cancer Council, Sydney 1998
   Google Scholar
• Lamb D. S., Denham J. W., Mameghan H., et al. Acceptability of short term neo‐adjuvant androgen deprivation in patients with locally advanced prostate cancer. Radiother Oncol 2003; 68: 255–67
   PubMed Web of Science ®Google Scholar
• New Zealand Health Information Service (NZHIS). NZHIS Cancer Statistics for 2002. Wellington, Ministry of Health, New Zealand
   Google Scholar
• Postma R., Schroder F. H., van Leenders G. J., et al. Cancer detection and cancer characteristics in the European Randomised Study of Screening for Prostate Cancer (ERSPC) – section Rotterdam. A comparison of two rounds of screening. Eur Urol 2007; 52: 89–97
   PubMed Web of Science ®Google Scholar
• Ciatto S., Gervasi G., Bonardi R., et al. Determining overdiagnosis by screening with DRE/TRUS or PSA (Florence pilot studies, 1991–1994). Eur J Cancer 2005; 41: 411–5
   PubMed Web of Science ®Google Scholar
• Etzioni R., Penson D. F., Legler J. M., et al. Overdiagnosis due to prostate‐specific antigen screening: lessons from US prostate cancer incidence trends. J Natl Cancer Inst 2002; 94: 958–60
   PubMedGoogle Scholar
• Leman E. S., Cannon G. W., Trock B. J., et al. EPCA‐2: a highly specific serum marker for prostate cancer. Urology 2007; 69: 714–20
   PubMed Web of Science ®Google Scholar
• Fink K. G., Hutarew G., Lumper W., et al. Prostate cancer detection with two sets of ten‐core compared to two sets of sextant biopsies. Urology 2001; 58: 735–9
   PubMed Web of Science ®Google Scholar
• Aus G., Bergdahl S., Lodding P., Lilja H., Hugosson J. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer – results from a prospective, population‐based randomized controlled trial. Eur Urol 2007; 51: 659–64
   PubMed Web of Science ®Google Scholar
• Bill‐Axelson A., Holmberg L., Ruutu M., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352: 1977–84
   PubMed Web of Science ®Google Scholar
• Greenlee R. T., Hill‐Harmon M. B., Murray T., Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 15–36
   PubMed Web of Science ®Google Scholar
• Oliver S. E., Gunnell D., Donovan J. L. Comparison of trends in prostate‐cancer mortality in England and Wales and the USA. Lancet 2000; 355: 1788–9
   PubMed Web of Science ®Google Scholar
• Oberaigner W., Horninger W., Klocker H., et al. Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate‐specific antigen testing. Am J Epidemiol 2006; 164: 376–84
   PubMed Web of Science ®Google Scholar
• Labrie F., Candas B., Cusan L., et al. Screening decreases prostate cancer mortality: 11‐year follow up of the 1998 Quebec prospective randomized controlled trial. Prostate 2004; 59: 311–8
   PubMed Web of Science ®Google Scholar
• Ilic D., O'Connor D., Green S., Wilt T. Screening for prostate cancer. Cochrane Database of Systematic Reviews 2006, (3), Art. CD004720
   PubMed Web of Science ®Google Scholar
• Schröder F. H. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Can J Urol 2005; 12: 2–6
   PubMedGoogle Scholar
• Auvinen A., Rietbergen J. B., Denis L. J., Schroder F. H., Prorok P. C. Prospective evaluation plan for randomised trials of prostate cancer screening. The International Prostate Cancer Screening Trial Evaluation Group. J Med Screen 1996; 3: 97–104
   PubMedGoogle Scholar
• Kramer B. S., Gohagan J., Prorok P. C., Smart C. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. Cancer 1993; 71: 589–93
   PubMed Web of Science ®Google Scholar
• de Koning H. J., Auvinen A., Sanchez A. B., et al. Large‐scale randomized prostate cancer screening trials: Program performances in the European Randomized Screening for Prostate Cancer Trial and the Prostate, Lung, Colorectal and Ovary Cancer Trial. Int J Cancer 2002; 97: 237–44
   PubMed Web of Science ®Google Scholar
• Schröder F. H., Denis L. J., Roobol M. The story of the European Randomised Study of Screening for Prostate Cancer. Br J Urol 2003; 92: 1–13
   Google Scholar
• de Koning H. J., Liem M. K., Baan C. A., et al. Prostate cancer mortality reduction by screening: Power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer 2002; 98: 268–73
   PubMed Web of Science ®Google Scholar
• de Vriers S. H., Postma R., Raaijmakers R., et al. Overall and disease‐specific survival of patients with screen‐detected prostate cancer in the European Randomized Study of Screening for Prostate Cancer, Section Rotterdam. Eur Urol 2007; 15: 366–74
   Web of Science ®Google Scholar
• Roemeling S., Roobol M. J., de Vries S. H., et al. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: Characteristics, PSA doubling times, and outcome. Eur Urol 2007; 51: 1244–51
   PubMed Web of Science ®Google Scholar
• Schröder F. H., Hermanek P., Denis L., et al. The TNM classification of prostate cancer. Prostate 1992; 4: 129–38
   Google Scholar
• Draisma G., Boer R., Otto S. J., et al. Lead times and overdetection due to prostate‐specific antigen screening: estimates from the European Randomised Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: 868–78
   PubMed Web of Science ®Google Scholar
• Andriole G. L., Reding D., Hayes R. B., et al. The Prostate, Lung, Colon and Ovarian (PLCO) cancer screening trial: status and promise. Urol Oncol 2004; 22: 358–61
   PubMed Web of Science ®Google Scholar
• NCI Division of Cancer Prevention. The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO). http://www.dcp.cancer.gov./programs‐resources/groups/ed/programs/plco (accessed September 2007)
   Google Scholar
• Andriole G. L., Levin D. L., Crawford E. D., et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings from the initial screening round of a randomized trial. J Nat Cancer Inst 2005; 97: 433–8
   PubMedGoogle Scholar
• Roemeling S., Roobol M. J., Otto S. J., et al. Feasibility study of adjustment for contamination and non‐compliance in a prostate cancer screening trial. Prostate 2007; 67: 1053–60
   PubMed Web of Science ®Google Scholar
• Baade P. D., Steginga S. K., Pinnock C. B., Aitken J. F. Communicating prostate cancer risk: what should we be telling our patients?. Med J Aust 2005; 182: 472–5
   PubMed Web of Science ®Google Scholar
• Roemeling S., Schroder F. H. Prevalence, treatment modalities and prognosis of familial prostate cancer in a screened population. J Urol 2006; 175: 1332–6
   PubMed Web of Science ®Google Scholar
• Carter B. S., Bova G. S., Beaty T. H. Hereditary prostate cancer: epidemiological and clinical features. J Urol 1993; 150: 797–802
   PubMed Web of Science ®Google Scholar
• Johns L. E., Houlston R. S. A systematic review and meta‐analysis of familial prostate cancer risk. Br J Urol 2003; 91: 789–94
   Google Scholar
• Morganti G., Gianferrari I., Cresserri A., Arrigoni G., Lovati G. Recherches clinico‐statistiques sur les neoplasias de la prostate. Acta Gent Stat Med 1956; 6: 304–5
   PubMedGoogle Scholar
• Zeegers M., Jellema A., Ostrer H. Empiric risk of prostate cancer for relatives of patients with prostate cancer; a meta‐analysis. Cancer 2003; 97: 1894–902
   PubMed Web of Science ®Google Scholar
• Staples M. P., Giles G. G., English D. R., et al. Risk of prostate cancer associated with a family history in an era of rapid increase in prostate cancer diagnosis (Australia). Cancer Causes Control 2003; 14: 161–6
   PubMed Web of Science ®Google Scholar
• Page W. F., Braun M. M., Partin A. W., Caporaso N., Walsh P. Heredity and prostate cancer: a study of World War II veteran twins. Prostate 1997; 33: 240–5
   PubMed Web of Science ®Google Scholar
• Lichenstein P., Holm N. V., Verkasalo P. K. Environmental and heritable factors in the causation of cancer – analysis of cohorts of twins in Sweden, Denmark and Finland. N Engl J Med 2000; 343: 78–85
   PubMed Web of Science ®Google Scholar
• Kupelian P. A., Reddy C. A., Reuther A. M., Mahadevan A., Ciezki J. P. Aggressiveness of familial prostate cancer. J Clin Oncol 2006; 24: 3445–50
   PubMed Web of Science ®Google Scholar
• Rodriguez C., Calle E. E., Miracle‐McMahill H. L., et al. Family history and risk of fatal prostate cancer. Epidemiology 1997; 8: 653–7
   PubMed Web of Science ®Google Scholar
• Marrotte J. B., Ferrari M. K., McNeal J. E. Time trends in pathological features of radical prostatectomy: impact of family history. Urol Oncol 2004; 22: 169–73
   PubMed Web of Science ®Google Scholar
• Delahunt B., Lamb D. S., Nacey J. N. The diagnosis and treatment of prostate cancer: will commonsense prevail. NZ J Med Lab Sci 2004; 58: 86–9
   Google Scholar
• Sakr W. A., Haas G. P., Cassin B. F., et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993; 150: 379–85
   PubMed Web of Science ®Google Scholar
• SEER Cancer Statistics 1973–1991: Tables and Graphs, LAG Ries, BA Miller, BF Hankey. National Cancer Institute, Bethesda 1994
   Google Scholar
• Wakui S., Furusato M., Kato H., et al. Nuclear bodies in human autopsy prostate with special reference to appearance rate. Anat Anzeiger 1991; 172: 297–307
   PubMedGoogle Scholar
• Delahunt B., Nacey J. N. Thin core biopsy of prostate. Pathology 1998; 30: 247–56
   PubMed Web of Science ®Google Scholar
• Rubin M. A., Zhou M., Dhanasekaran S. M., et al. Alpha‐methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002; 287: 1662–70
   PubMed Web of Science ®Google Scholar
• Lamb D. S., Denham J. W., Delahunt B. Prostate cancer screening in Australasia. Clin Oncol 2005; 17: 231–3
   Web of Science ®Google Scholar
• Gleason D. F. Classification of prostatic carcinoma. Cancer Chemother Rep 1966; 50: 125–8
   PubMedGoogle Scholar
• Gleason D. F., the Veterans Administration Cooperative Urological Research Group. Histologic grading and clinical staging of prostatic carcinoma. Urologic Pathology, M Tannenbaum. Lea & Febiger, Philadelphia 1977
   Google Scholar
• Bostwick D. G., Srigley J., Grignon D., et al. Atypical adenomatous hyperplasia of the prostate: morphologic criteria for its distinction from well differentiated carcinoma. Hum Pathol 1993; 24: 819–32
   PubMed Web of Science ®Google Scholar
• Mittal B. V., Amin M. B., Kinare S. G. Spectrum of histological lesion in 185 consecutive prostatic specimens. J Postgrad Med 1989; 35: 157–61
   PubMedGoogle Scholar
• Epstein J. I., Armas O. A. Atypical basal cell hyperplasia of the prostate. Am J Surg Pathol 1992; 16: 1205–14
   PubMed Web of Science ®Google Scholar
• Civantos F., Marcial M. A., Banks E. R., et al. Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients. Cancer 1995; 75: 1634–41
   PubMed Web of Science ®Google Scholar
• Gagucas R. J., Brown R. W., Wheeler T. M. Verumontanum mucosal gland hyperplasia. Am J Surg Pathol 1995; 19: 30–6
   PubMed Web of Science ®Google Scholar
• Bostwick D. G., Cheng L. Overdiagnosis of prostate adenocarcinoma. Semin Urol Oncol 1999; 17: 199–205
   PubMedGoogle Scholar
• lbertsen P. C., Harley J. A., Gleason D. F., Barry M. F. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 975–80
   PubMed Web of Science ®Google Scholar
• Lapointe J., Li C., Higgins J. P., et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004; 101: 811–6
   PubMed Web of Science ®Google Scholar
• True L., Coleman I., Hawley S., et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci USA 2006; 103: 10991–6
   PubMed Web of Science ®Google Scholar
• Partin A. W., Piantadosi S., Sanda M. G., et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 1995; 45: 831–8
   PubMed Web of Science ®Google Scholar
• Blute M. L., Bergstralh E. J., Iocca A., et al. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001; 165: 119–25
   PubMed Web of Science ®Google Scholar
• D'Amico A. V., Chen M. H., Roehl K. A., Catalona W. J. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351: 125–35
   PubMed Web of Science ®Google Scholar